These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 22967182)

  • 1. Toward a predictive model of Alzheimer's disease progression using capillary electrophoresis-mass spectrometry metabolomics.
    Ibáñez C; Simó C; Martín-Álvarez PJ; Kivipelto M; Winblad B; Cedazo-Mínguez A; Cifuentes A
    Anal Chem; 2012 Oct; 84(20):8532-40. PubMed ID: 22967182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new metabolomic workflow for early detection of Alzheimer's disease.
    Ibáñez C; Simó C; Barupal DK; Fiehn O; Kivipelto M; Cedazo-Mínguez A; Cifuentes A
    J Chromatogr A; 2013 Aug; 1302():65-71. PubMed ID: 23827464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease.
    Greenberg N; Grassano A; Thambisetty M; Lovestone S; Legido-Quigley C
    Electrophoresis; 2009 Apr; 30(7):1235-9. PubMed ID: 19288586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
    de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
    J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolomic profiling of serum in the progression of Alzheimer's disease by capillary electrophoresis-mass spectrometry.
    González-Domínguez R; García A; García-Barrera T; Barbas C; Gómez-Ariza JL
    Electrophoresis; 2014 Dec; 35(23):3321-30. PubMed ID: 25136972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.
    Parnetti L; Lanari A; Silvestrelli G; Saggese E; Reboldi P
    Mech Ageing Dev; 2006 Feb; 127(2):129-32. PubMed ID: 16274728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
    Höglund K; Hansson O; Buchhave P; Zetterberg H; Lewczuk P; Londos E; Blennow K; Minthon L; Wiltfang J
    Neurodegener Dis; 2008; 5(5):268-76. PubMed ID: 18309230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
    Hansson O; Buchhave P; Zetterberg H; Blennow K; Minthon L; Warkentin S
    Neurobiol Aging; 2009 Feb; 30(2):165-73. PubMed ID: 17646035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.
    Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J
    J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.
    Hansson O; Zetterberg H; Vanmechelen E; Vanderstichele H; Andreasson U; Londos E; Wallin A; Minthon L; Blennow K
    Neurobiol Aging; 2010 Mar; 31(3):357-67. PubMed ID: 18486992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
    Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
    Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
    Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
    Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of chiral amino acids in cerebrospinal fluid samples linked to different stages of Alzheimer disease.
    Samakashvili S; Ibáñez C; Simó C; Gil-Bea FJ; Winblad B; Cedazo-Mínguez A; Cifuentes A
    Electrophoresis; 2011 Oct; 32(19):2757-64. PubMed ID: 21983823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease.
    Jung SM; Lee K; Lee JW; Namkoong H; Kim HK; Kim S; Na HR; Ha SA; Kim JR; Ko J; Kim JW
    Neurosci Lett; 2008 May; 436(2):153-7. PubMed ID: 18378077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment.
    Simonsen AH; McGuire J; Hansson O; Zetterberg H; Podust VN; Davies HA; Waldemar G; Minthon L; Blennow K
    Arch Neurol; 2007 Mar; 64(3):366-70. PubMed ID: 17353378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF.
    Spellman DS; Wildsmith KR; Honigberg LA; Tuefferd M; Baker D; Raghavan N; Nairn AC; Croteau P; Schirm M; Allard R; Lamontagne J; Chelsky D; Hoffmann S; Potter WZ; ;
    Proteomics Clin Appl; 2015 Aug; 9(7-8):715-31. PubMed ID: 25676562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Searching for urine biomarkers of bladder cancer recurrence using a liquid chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry metabolomics approach.
    Alberice JV; Amaral AF; Armitage EG; Lorente JA; Algaba F; Carrilho E; Márquez M; García A; Malats N; Barbas C
    J Chromatogr A; 2013 Nov; 1318():163-70. PubMed ID: 24139504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].
    Robert PH; Schuck S; Dubois B; Lépine JP; Gallarda T; Olié JP; Goni S; Troy S
    Encephale; 2003; 29(3 Pt 1):266-72. PubMed ID: 12876552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.
    Hansson O; Zetterberg H; Buchhave P; Andreasson U; Londos E; Minthon L; Blennow K
    Dement Geriatr Cogn Disord; 2007; 23(5):316-20. PubMed ID: 17374949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.